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Background: Most patients presenting with acute exacerbations of chronic obstructive pulmonary disease
(AECOPD) in primary care are prescribed antibiotics, but these may not be beneficial, and they can cause
side effects and increase the risk of subsequent resistant infections. Point-of-care tests (POCTs) could safely
reduce inappropriate antibiotic prescribing and antimicrobial resistance.
Objective: To determine whether or not the use of a C-reactive protein (CRP) POCT to guide prescribing
decisions for AECOPD reduces antibiotic consumption without having a negative impact on chronic
obstructive pulmonary disease (COPD) health status and is cost-effective.
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Design: A multicentre, parallel-arm, randomised controlled open trial with an embedded process, and a
health economic evaluation.
Setting: General practices in Wales and England. A UK NHS perspective was used for the economic analysis.
Participants: Adults (aged ≥ 40 years) with a primary care diagnosis of COPD, presenting with an
AECOPD (with at least one of increased dyspnoea, increased sputum volume and increased sputum
purulence) of between 24 hours’ and 21 days’ duration.
Intervention: CRP POCTs to guide antibiotic prescribing decisions for AECOPD, compared with usual care
(no CRP POCT), using remote online randomisation.
Main outcome measures: Patient-reported antibiotic consumption for AECOPD within 4 weeks post
randomisation and COPD health status as measured with the Clinical COPD Questionnaire (CCQ) at
2 weeks. For the economic evaluation, patient-reported resource use and the EuroQol-5 Dimensions
were included.
Results: In total, 653 participants were randomised from 86 general practices. Three withdrew consent and
one was randomised in error, leaving 324 participants in the usual-care arm and 325 participants in the CRP
POCT arm. Antibiotics were consumed for AECOPD by 212 out of 274 participants (77.4%) and 150 out of
263 participants (57.0%) in the usual-care and CRP POCT arm, respectively [adjusted odds ratio 0.31, 95%
confidence interval (CI) 0.20 to 0.47]. The CCQ analysis comprised 282 and 281 participants in the usual-care
and CRP POCT arms, respectively, and the adjusted mean CCQ score difference at 2 weeks was 0.19 points
(two-sided 90% CI –0.33 to –0.05 points). The upper limit of the CI did not contain the prespecified non-
inferiority margin of 0.3. The total cost from a NHS perspective at 4 weeks was £17.59 per patient higher in
the CRP POCT arm (95% CI –£34.80 to £69.98; p = 0.408). The mean incremental cost-effectiveness ratios
were £222 per 1% reduction in antibiotic consumption compared with usual care at 4 weeks and £15,251
per quality-adjusted life-year gained at 6 months with no significant changes in sensitivity analyses. Patients
and clinicians were generally supportive of including CRP POCT in the assessment of AECOPD.
Conclusions: A CRP POCT diagnostic strategy achieved meaningful reductions in patient-reported
antibiotic consumption without impairing COPD health status or increasing costs. There were no
associated harms and both patients and clinicians valued the diagnostic strategy.
Future work: Implementation studies that also build on our qualitative findings could help determine the
effect of this intervention over the longer term.
Trial registration: Current Controlled Trials ISRCTN24346473.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 15.
See the NIHR Journals Library website for further project information.
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A&E accident and emergency
AE adverse event
AECOPD acute exacerbation of chronic
obstructive pulmonary disease
AMD adjusted mean difference
AOR adjusted odds ratio
CACE complier average causal effect
CCQ Clinical COPD Questionnaire
CI confidence interval
COPD chronic obstructive
pulmonary disease
CRF case report form
CRN Clinical Research Network
CRP C-reactive protein
CRQ-SAS Chronic Respiratory Disease
Questionnaire Self-Administered
Standardized
CSRI Client Service Receipt Inventory
CUA cost–utility analysis
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GP general practitioner
HRQoL health-related quality of life
ICER incremental cost-effectiveness ratio
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ITT intention to treat
LRTI lower respiratory tract infection
MITT modified intention to treat
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
PACE Primary care use of A C-reactive
protein point of care test to help
target antibiotic prescribing to
patients with acute Exacerbations
of chronic obstructive pulmonary
disease who are most likely
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POCT point-of-care test
PPI patient and public involvement
PSSRU Personal Social Services Research Unit
QALY quality-adjusted life-year
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SAE serious adverse event
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Plain English summary
People with chronic obstructive pulmonary disease (COPD) often experience flare-ups known as acuteexacerbations of chronic obstructive pulmonary disease. Antibiotics are prescribed for most flare-ups,
but they do not always benefit patients and may cause harm, such as side effects or subsequent infections
that are resistant.
Rapid point-of-care tests (POCTs) can be used to help determine when antibiotics are more likely to be
needed. C-reactive protein (CRP) is a marker of inflammation that can be measured with a POCT. Patients
with flare-ups and a low CRP value are less likely to benefit from antibiotics. The PACE trial asked whether
or not measuring CRP with a POCT could lead to fewer antibiotics being consumed for flare-ups, without
having negative effects for patients.
We aimed to recruit 650 patients with a COPD flare-up from primary care. Patients were randomly
assigned to either (1) usual care with the addition of a CRP POCT, or (2) usual care without the addition
of the test. Antibiotic use over the first 4 weeks and patients’ self-assessment of their health 2 weeks
after enrolment were measured in both groups.
Patients in the CRP test group used fewer antibiotics than those managed as usual, and had improved
patient-reported outcomes. Costs were a little higher in the CRP POCT group. Interviews with patients
and clinicians found that they appreciated the CRP test being included in the decision-making process.
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Scientific summary
Background
Unnecessary antibiotic use drives antimicrobial resistance, wastes resources, may cause adverse effects
and may distract from potentially more effective interventions for individuals. Point-of-care tests (POCTs)
for acute infections are being promoted by government, by industry and in clinical guidelines to reduce
inappropriate antibiotic prescribing, help contain antimicrobial resistance and improve patient outcomes.
However, most evaluations of POCTs have examined analytic performance only, and there have been few
trials evaluating clinical effectiveness and cost-effectiveness in the context in which POCTs are intended to
be used. About 4.5% of the population over the age of 45 years live with diagnosed chronic obstructive
pulmonary disease (COPD), and about half of these people experience one or more acute exacerbations
of chronic obstructive pulmonary disease (AECOPD) that require medical treatment each year. Over 2 million
antibiotic courses are prescribed for AECOPD each year in the UK, and most of these are issued in primary
care. Although some patients with AECOPD are helped by these prescriptions, many are not, and so some
antibiotics may simply damage the microbiome. Among patients admitted to hospital, a bacterial aetiology
was identified in 30%, a viral agent was identified in 23%, both bacterial and viral agents were identified
in a further 25%, and 20% of the AECOPDs were caused by other factors. The antibiotic prescribing
recommendations for primary care management of AECOPD are generally based on clinical features alone
(Anthonisen criteria, namely increased breathlessness, increased sputum volume and increased sputum
purulence) (Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic
therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204).
These features are subjective and have insufficient diagnostic accuracy to predict which patients can safely
be managed without antibiotics.
C-reactive protein (CRP) is an acute phase protein that rises rapidly in infections and can be measured
easily at the point of care, and it is considered the most selective biomarker to confirm AECOPD.
A randomised controlled trial in primary care found no difference in clinical cure between patients
with AECOPD treated with antibiotics and those treated with placebo who had a CRP level of < 40 mg/l.
The availability of CRP POCT results may, therefore, help guide prescribing decisions for AECOPD to reduce
antibiotic consumption, reduce antimicrobial resistance and improve patient outcomes. However, the
clinical effectiveness and cost-effectiveness of CRP POCT have not yet been evaluated in a pragmatic
controlled trial in primary care.
Objective
We aimed to establish whether or not the addition of a CRP POCT to usual care for AECOPD in primary
care safely and cost-effectively reduces antibiotic consumption for AECOPD.
Methods
Trial design
The PACE (Primary care use of A C-reactive protein point-of-care test to help target antibiotic prescribing
to patients with acute Exacerbations of chronic obstructive pulmonary disease who are most likely to
benefit) trial was a multicentre, parallel-arm, individually randomised controlled open trial with embedded
health economics and qualitative process evaluations, conducted between September 2015 and
February 2017 in UK general medical practices.
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Intervention guidance
All participating sites were provided with information on the current best practice for managing AECOPD,
which included a brief summary of National Institute for Health and Care Excellence and the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidance, and were provided with a desktop CRP POCT Afinion
device [Alere AfinionTM AS100 Analyzer, Alere Inc. (now Abbott Diagnostics), IL, USA]. Clinicians were given
training in the use of the POCT and guidance on interpreting the test results, which emphasised that the
decision about antibiotic prescribing should be based on a comprehensive assessment of the likely risks and
benefits, given the patient’s underlying health status and clinical features. In addition, the guidance indicated
that for patients with a CRP level of < 20 mg/l, antibiotics are unlikely to be beneficial and usually should not
be prescribed; for patients with a CRP level of 20–40mg/l, antibiotics may be beneficial, mainly if purulent
sputum is present; and for patients with a CRP level of > 40 mg/l, antibiotics are likely to be beneficial.
Eligibility, recruitment and randomisation
Men or women were eligible if they were aged ≥ 40 years, had a primary care diagnosis of COPD, presented
with an AECOPD (with at least one of increased dyspnoea, increased sputum volume and increased sputum
purulence) of between 24 hours’ and 21 days’ duration, and provided informed, written consent.
Participants were allocated to the trial arms using remote online computerised randomisation.
Data collection
Baseline data collected included the number of days the patient had AECOPD symptoms, the patient’s
medical history and clinicians’ examination findings.
A sputum sample, when obtainable, and throat swab samples were taken, and participants self-completed
the Clinical COPD Questionnaire (CCQ) and the EuroQol 5-Dimensions (EQ-5D) questionnaire prior to
randomisation. Clinicians recorded their antibiotic prescribing and other management decisions for all
participants after randomisation and assessment.
Participants were followed up with telephone calls at week 1 and week 2, and a face-to-face consultation
at 4 weeks post randomisation, during which a further throat swab and sputum sample (when available)
were taken. At 6 months, the Chronic Respiratory Disease Questionnaire Self-Administered Standardized
(CRQ-SAS) and EQ-5D questionnaires were posted to participants, who completed these and returned
them using provided stamped addressed envelopes, and we collected relevant data from electronic
medical records.
Clinicians were asked to carry out a CRP POCT as part of their assessment of participants allocated to the
intervention (CRP POCT arm). For patients allocated to usual care (control arm), clinicians were asked not
to use CRP POCT in their management of those patients’ AECOPD at any time during participation.
Outcome measures
We used two co-primary outcomes because any reduction in antibiotic consumption would have to
be considered alongside any negative impact on patient recovery. The first co-primary outcome was
patient-reported antibiotic consumption for AECOPD within 4 weeks post randomisation. The second
co-primary outcome was COPD health status (total score) measured with the CCQ at 2 weeks post
randomisation.
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Sample size
The study aimed to have sufficient power to detect a 15% reduction from an estimated 70% of patients
consuming antibiotics for AECOPD during the 4 weeks following randomisation, and sufficient power
to demonstrate that participants managed with the CRP POCT do no worse (non-inferior) than those
managed without the CRP POCT, in terms of their COPD health status measured with the CCQ 2 weeks
post randomisation. Assuming an expected difference between the arms of zero, a non-inferiority margin of
0.3 [smaller than the lowest minimal clinically important difference and a common standard deviation (SD)
of 1.1], based on a one-sided significance level of 0.05 and 90% power, the study needed 462 participants,
inflated to 580 to account for the loss to follow-up of approximately 20% of participants. It was also
anticipated that the outcomes would not be entirely independent. Therefore, we aimed to recruit at least
650 participants to maintain an overall power between 81% and 90%.
Clinical effectiveness and cost-effectiveness analyses
The main clinical effectiveness analysis was based on a modified intention-to-treat population, which
included all randomised participants who provided outcome data, regardless of protocol deviations or
intervention received. All planned analyses were described in detail in a statistical analysis plan.
A within-trial health economic analysis was undertaken from a UK NHS perspective that assessed CRP
POCT implementation costs in primary care and subsequent health-care costs within the trial follow-up
period of 6 months. A cost-effectiveness analysis based on the co-primary outcome of antibiotic
consumption at 4 weeks and a cost–utility analysis at 6 months were performed. Furthermore, a
cost–consequences analysis and a budget impact analysis were conducted and the robustness of the
results was tested in sensitivity analyses.
Process evaluation
A qualitative process evaluation was undertaken to facilitate the interpretation of results and assist with
implementation planning. Semistructured telephone interviews were carried out with 20 purposively
sampled patients and 20 primary care staff. A topic guide focused on experiences of the management of
AECOPD, the acceptability, implementation and potential mechanisms of the CRP POCT intervention and
contextual factors that could influence future implementation. Audio-recordings were transcribed verbatim
and analysed using framework analysis.
Results
Baseline characteristics
In total, 653 participants were randomised from 86 general practices between January 2015 and
February 2017. Three withdrew consent and one was randomised in error (the patient had been
randomised, but the clinician then noted that this patient was ineligible and so their baseline data were
destroyed), leaving 324 usual-care and 325 CRP POCT participants. The mean age was 68.1 (SD 9.42)
years; 51.6% of participants were men; 10.8% of participants had mild COPD (GOLD I), 54.8% of
participants had moderate COPD (GOLD II), 28.1% of participants had severe COPD (GOLD III) and
6.3% of participants had very severe COPD (GOLD IV); the mean ratio of forced expiratory volume in
1 second (FEV1) to forced vital capacity (FVC) was 0.6 (SD 0.13); the mean percentage predicted FEV1 was
59.8% (SD 20.04%); the mean number of days with symptoms prior to consultation was 6.9 (SD 5.13) days;
the mean baseline CCQ total score was 3.3 (SD 1.14) points; and the baseline health utility (EQ-5D) was
0.7 (SD 0.25). Overall, no pathogens were detected in 95 out of 386 baseline sputum samples (24.6%),
bacterial pathogens were only detected in 79 out of 386 (20.5%), viral/atypical pathogens were only
detected in 123 out of 386 cases (31.9%) and both bacterial and viral/atypical pathogens were detected
in 89 out of 386 cases (23.1%). Participants in both trial arms were well matched for these and other
characteristics at baseline.
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Primary outcome
In total, 537 out of the 649 randomised participants contributed to the primary analysis of self-reported
antibiotic consumption at 4 weeks post randomisation (82.7%), and 563 contributed to the primary
analysis of CCQ total score at 2 weeks post randomisation (86.7%). Antibiotics were consumed for
AECOPD by 212 (77.4%) usual-care participants and 150 (57.0%) CRP POCT participants [adjusted odds
ratio (AOR) 0.31, 95% confidence interval (CI) 0.20 to 0.47]. The adjusted mean CCQ score difference
at 2 weeks was –0.19 (two-sided 90% CI –0.33 to –0.05) points. The upper limit of the CI did not contain
the prespecified non-inferiority margin of 0.3.
Antibiotic prescribing at index consultation and 4-week follow-up
Antibiotic prescribing at the index consultation was ascertained for all but one participant, and 22% fewer
participants in the CRP POCT arm were prescribed antibiotics (47.7% in the usual-care arm vs. 69.7%
in the CRP POCT arm, AOR 0.31, 95% CI 0.21 to 0.45), and 21% fewer participants were prescribed
antibiotics over the 4-week follow-up (59.1% vs. 79.7%, AOR 0.30, 95% CI 0.20 to 0.46).
Antibiotic prescribing and C-reactive protein values at index consultation
A total of 97.5% (317/325) of participants allocated to the CRP POCT arm reported receiving a CRP
POCT during the recruitment consultation, and the median CRP value was 6 mg/l (interquartile range
5–18.5 mg/l); 76.0% of participants (241/317) had CRP levels of < 20 mg/l. Antibiotics were prescribed
for 33% of those patients with a CRP level of < 20 mg/l in the CRP POCT arm at the index consultation.
Secondary outcomes
There was no evidence of a difference between the arms regarding symptoms sometimes attributed as
adverse effects from antibiotics and other COPD treatments (AOR 0.79, 95% CI 0.44 to 1.39; p = 0.410),
primary or secondary care consultations during the 6 months following randomisation (AOR 1.39, 95% CI
0.46 to 4.15; p = 0.559), or pneumonia diagnoses at 4 weeks (AOR 1.57, 95% CI 0.28 to 8.84; p = 0.608)
and 6 months (AOR 0.73, 95% CI 0.29 to 1.82; p = 0.495). There was no evidence to conclude that there
were any differences between the arms for CRQ-SAS outcomes at 6 months.
No meaningful or statistically significant differences were found between the arms at 1 month in the
potential pathogens and antibiotic resistant isolates from sputum, or in resistance in commensal and
potentially pathogenic organisms isolated from throat swabs.
Adverse events
Two participants, both in the usual-care arm, died during the first 4 weeks following randomisation:
these serious adverse events were not related to the intervention or to trial participation.
Economic evaluation
Reduced antibiotic costs at the initial consultation were offset by higher total medication costs over the
following 6 months, mainly caused by a 5.4% increase in prescribing of inhaled medication in the CRP
POCT arm. COPD-related primary care contacts were lower in the intervention arm, with 2.7% fewer
general practitioner visits. Although outpatient attendances were reduced in the CRP POCT arm (4.1%
fewer appointments at 4 weeks and 6.7% fewer at 6 months), the secondary care cost for any condition
was higher for all follow-up periods as a result of increased inpatient length of stay for a small number of
intervention patients. The total incremental cost was £17.59 at 4 weeks and £126.26 at 6 months, driven
mainly by the higher inpatient cost and the cost of CRP testing. If only COPD-related health-care costs are
considered, the cost in both arms was similar, with the CRP test cost of £11.31 per test slightly offset by
savings in health-care resource use. The mean incremental cost-effectiveness ratios were £222 (95% CI
–£42.00 to £518.14) per 1% reduction in antibiotic consumption compared with usual care at 4 weeks
and £15,251 (95% CI £2959 to £22,813) per quality-adjusted life-year gained at 6 months. Patients in
the CRP POCT arm had fewer days off work, with reduced costs of productivity loss of £510.42 (95% CI
–£989.56 to –£31.28; p = 0.022) per patient reporting periods of worktime missed.
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Process evaluation
Patients participating in the qualitative evaluation felt that the CRP POCT was useful in detecting
infection and targeting treatment more appropriately, and that it seemed quick and easy to use. Clinicians
reported enhanced confidence in making management decisions and reduced decisional ambiguity
when withholding antibiotics, and felt that the CRP POCT was a useful tool for communicating with and
reassuring patients. They were keen to emphasise that the test should be used alongside, and not as a
replacement for, clinical assessment. Cartridge preparation time and the cost of the equipment presented
a significant barrier when implementing the test.
Conclusions
A CRP POCT diagnostic strategy resulted in a 20% absolute reduction in patient-reported antibiotic
consumption over 4 weeks and in clinician antibiotic prescribing at the index consultation, and no clinically
important change in patient-reported condition-specific quality of life, without evidence of an increase
in total COPD-related costs. The use of the CRP POCT strategy was broadly acceptable to patients and
clinicians. There were no associated harms identified in the trial, although clinicians indicated that the
time and costs associated with the CRP POCT needed careful consideration.
Awareness of receiving the POCT may have contributed to enhanced COPD health status; however,
this real-world effect needed to be captured. As awareness of intervention allocation may have an impact
on participant help-seeking, and, as capturing this is critical to assessments of cost-effectiveness, this was
an open trial.
C-reactive protein POCT strategies in primary care have been shown to safely and cost-effectively reduce
antibiotic prescribing for acute cough; however, only a small minority of participants in those studies had
AECOPD, and none reported effects on antibiotic consumption rather than antibiotic prescribing.
We confirmed that bacterial infection is a likely trigger for AECOPD in a minority of patients, and that
there may be potential for further safe reductions in antibiotic use for AECOPD, given that one-third of
participants with a CRP level of < 20 mg/l were nevertheless prescribed antibiotics.
This trial provides good evidence that CRP POCT testing (with the associated guidance for clinicians that
was used in this trial) to guide antibiotic prescribing decisions for AECOPD in primary care is safe and
effective. Further research, building on our qualitative findings, could help guide effective implementation.
Trial registration
This trial is registered as ISRCTN24346473.
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